高盛：医疗保健板块整体难有作为，但“浪里淘金”仍有机会

智通财经11-11

智通财经APP获悉，高盛集团策略师大卫·科斯廷表示，医疗保健板块的下跌为选股者创造了机会，但该板块难以出现整体性上涨。今年以来，医疗保健板块(XLV)表现落后标普500指数8个百分点，并有望连续第三年跑输大盘。即使剔除超大盘科技股的影响，该板块相对于宽基指数的估值折价幅度仍接近历史极值。科斯廷指出，虽然低估值暗示存在潜在上行空间，但稳健的经济增长、人工智能热潮以及政策不确定性可能会限制板块整体表现...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2582330449?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-11 14:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582330449","market":"us","top_or_hot":-1,"title":"高盛：医疗保健板块整体难有作为，但“浪里淘金”仍有机会","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，高盛集团策略师大卫·科斯廷表示，医疗保健板块的下跌为选股者创造了机会，但该板块难以出现整体性上涨。今年以来，医疗保健板块(XLV)表现落后标普500指数8个百分点，并有望连续第三年跑输大盘。即使剔除超大盘科技股的影响，该板块相对于宽基指数的估值折价幅度仍接近历史极值。科斯廷指出，虽然低估值暗示存在潜在上行空间，但稳健的经济增长、人工智能热潮以及政策不确定性可能会限制板块整体表现...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1367690.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>高盛：医疗保健板块整体难有作为，但“浪里淘金”仍有机会</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n高盛：医疗保健板块整体难有作为，但“浪里淘金”仍有机会\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-11 14:45 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1367690.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，高盛集团策略师大卫·科斯廷表示，医疗保健板块的下跌为选股者创造了机会，但该板块难以出现整体性上涨。今年以来，医疗保健板块(XLV)表现落后标普500指数8个百分点，并有望连续第三年跑输大盘。即使剔除超大盘科技股的影响，该板块相对于宽基指数的估值折价幅度仍接近历史极值。科斯廷指出，虽然低估值暗示存在潜在上行空间，但稳健的经济增长、人工智能热潮以及政策不确定性可能会限制板块整体表现...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1367690.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0345770308.USD","symbol_name":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1367690.html","article_id":"2582330449","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582330449","pubTimestamp":1762843541,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，高盛集团策略师大卫·科斯廷表示，医疗保健板块的下跌为选股者创造了机会，但该板块难以出现整体性上涨。在高盛并购概念股组合中，近半数为医疗保健公司，该行预计并购活动将持续增长至明年。在个股层面，高盛筛选出罗素1000指数中的一些医疗保健股，这些个股近期均获机构上调2026年每股收益预测，且当前估值低于历史水平。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","BK4588":"碎股","BK4550":"红杉资本持仓","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","BK4552":"Archegos爆仓风波概念","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","IE0004086264.USD":"BNY MELLON GLOBAL OPPORTUNITIES \"A\" (USD) ACC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","IE0004091025.USD":"BNY MELLON GLOBAL OPPORTUNITIES \"B\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","BK4581":"高盛持仓","XLV":"健康照护类股ETF-SPDR","LU0251131958.USD":"FIDELITY AMERICA \"A\" (USD) ACC","LU0106831901.USD":"贝莱德世界金融基金A2","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU2471134879.HKD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (HKD) INC","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","LU0742534661.SGD":"Fidelity America A-SGD (hedged)","BK4585":"ETF&股票定投概念","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","BK4127":"投资银行业与经纪业","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","XBI":"SPDR S&P Biotech ETF","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU0251142724.SGD":"Fidelity America A-SGD","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","BK4516":"特朗普概念","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU2750360997.AUD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (AUDHDG) INC","LU1791807156.HKD":"BGF WORLD FINANCIALS \"A2\" (HKDHDG) ACC","LU0048573561.USD":"FIDELITY AMERICA \"A\" (USD) INC","LABU":"三倍做多标普生物-Direxion","BK4504":"桥水持仓"},"translate_title":"Goldman Sachs: The healthcare sector as a whole is difficult to make a difference, but there are still opportunities for \"gold rush in the waves\"","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XLV":1,"LABU":0.6,"XBI":0.6},"content_text":"智通财经APP获悉，高盛集团策略师大卫·科斯廷表示，医疗保健板块的下跌为选股者创造了机会，但该板块难以出现整体性上涨。今年以来，医疗保健板块(XLV)表现落后标普500指数8个百分点，并有望连续第三年跑输大盘。即使剔除超大盘科技股的影响，该板块相对于宽基指数的估值折价幅度仍接近历史极值。科斯廷指出，虽然低估值暗示存在潜在上行空间，但稳健的经济增长、人工智能热潮以及政策不确定性可能会限制板块整体表现。相反，他认为\"阿尔法收益的机会远大于贝塔收益\"，并指出回报率差异扩大和医疗保健行业并购交易活跃将成为精选个股的驱动因素。在高盛并购概念股组合中，近半数为医疗保健公司，该行预计并购活动将持续增长至明年。在个股层面，高盛筛选出罗素1000指数中的一些医疗保健股，这些个股近期均获机构上调2026年每股收益预测，且当前估值低于历史水平。以下是高盛筛选出的具体名单：爵士制药 (JAZZ.US)、因苏莱 (PODD.US)、索泰拉健康 (SHC.US)、因塞特 (INCY.US)、再生元制药 (REGN.US)、拜玛林制药 (BMRN.US)、环球健康服务 (UHS.US)、医生社交网络 (DOCS.US)、内分泌生物科学 (NBIX.US)、福泰制药 (VRTX.US)、因美纳 (ILMN.US)、西氏医药服务 (WST.US)、达维塔 (DVA.US)、爱德华兹生命科学 (EW.US)、礼来 (LLY.US)、捷迈邦美控股 (ZBH.US)、半影 (PEN.US)、艾视健控股 (NVST.US)、美敦力 (MDT.US)、Veeva系统 (VEEV.US)、麦斯莫 (MASI.US)、辉瑞 (PFE.US)、赛默飞世尔科技 (TMO.US)、瑞思迈 (RMD.US)、伯乐实验室 (BIO.US)、赛塔拉 (CERT.US)、艾利科技 (ALGN.US)、查尔斯河实验室国际 (CRL.US)、豪洛捷 (HOLX.US)。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582330449","isCrawlerRequest":true}